Bellicum Pharmaceuticals, Inc. - Common Stock BLCM announces its next round of earnings this Tuesday, March 12. Here's Benzinga's advanced look at Bellicum's Q4 earnings report.
Earnings and Revenue
Bellicum EPS is expected to be around a loss of 56 cents per share, according to sell-side analysts. Sales will likely be near $1.19 million.
In the same quarter last year, Bellicum announced EPS loss of 61 cents. Bellicum's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -0.58 | -0.55 | -0.69 | -0.7 |
| EPS Actual | -0.55 | -0.6 | -0.68 | -0.61 |
Stock Performance
Over the last 52-week period, shares are down 61.23 percent. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with Bellicum. The strength of this rating has maintained conviction over the past three months.
Conference Call
Bellicum's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/blcm/mediaframe/29021/indexl.html
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
